Emergent BioSolutions has received more than $250M in contract modifications from the Administration for Strategic Preparedness and Response – ASPR – at the U.S. Department of Health and Human Services, to deliver millions of doses of four medical countermeasures. These contract modifications will help ensure continued supply/stockpiling of critical MCMs to address biological threats and emergencies against anthrax, smallpox and botulism.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EBS:
- Emergent BioSolutions Awarded $250+ Million in Contract Modifications to Supply U.S. Government with Four Critical Medical Countermeasure Products
- Emergent BioSolutions Announces Baltimore Facility Sale and Employee Transition
- Emergent BioSolutions sells Baltimore-Camden site to Bora for $30M
- Emergent BioSolutions Announces Sale of Baltimore-Camden Manufacturing Site to Bora Pharmaceuticals for $30 Million
- Emergent BioSolutions price target raised to $8 from $5 at Benchmark